US prediction models for kidney injury following angioplasty hold up in Japan

April 04, 2016

Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan. This finding suggests these models may have international application as a preventive tool, according to a study published today in the Journal of the American College of Cardiology.

Acute kidney injury is a condition characterized by an abrupt or rapid decline in kidney function. It is the most common non-cardiac complication following angioplasty and is associated with an increased risk of other complications, as well as death. This condition often can be prevented, however, by administering fluids and using cholesterol-lowering medications before conducting the procedure. By knowing who is at highest risk for acute kidney injury, it is possible to take these steps and prevent this complication.

The prediction models from the NCDR CathPCI Registry were applied to records from 11,041 patients from the Japan Cardiovascular Database, a registry comprised of 16 centers, between September 2008 and May 2014. The acute kidney injury model used 11 variables for predicting this complication, including age, baseline presence of kidney impairment, a history of stroke or heart failure, and prior angioplasty. The acute kidney model involving dialysis used five variables: baseline presence of kidney impairment, diabetes, heart failure, presence of acute coronary syndrome, and cardiogenic shock.

Researchers found 10.1 percent of the patients experienced acute kidney injury and 1.5 percent had a kidney injury that required dialysis. Patients who experienced an acute kidney injury tended to be older, have more heart failure and kidney dysfunction prior to angioplasty, and a greater number of other medical conditions.

The study found that overall, the prediction model for acute kidney injury performed well. In the highest-risk group, the predicted incidence of acute kidney injury was 34 percent, compared to a 36 percent actual occurrence of the problem. Similar performance was observed among patients with and without acute coronary syndrome.

For patients with acute kidney injury requiring dialysis, the predicted risk was 4 percent, compared to a 9 percent observed incidence. This discrepancy showed that the model underestimated the risk of dialysis among the highest-risk patients. Once the model was adjusted properly, it was better able to stratify risk.

Taku Inohara, M.D., the study's lead author and a cardiologist at Keio University School of Medicine in Tokyo, said that "these findings support the use of the NCDR models in Japan" and pointed out that knowing a patient's risk for acute kidney injury enables the provider to tailor treatment accordingly. "Given the validity of the NCDR acute kidney injury models in Japan, future research on how to best leverage these insights about patient risk to minimize the onset of acute kidney injury is warranted," he said.

"This is an example of how registries, like NCDR, can provide important information that once it is validated--as it is in this paper--can change practice," said Valentin Fuster, M.D., Ph.D., Journal of the American College of Cardiology editor-in-chief.

In an accompanying editorial, Peter A. McCullough, M.D., M.P.H., FACC, vice chief of medicine at Baylor University Medical Center in Dallas, said that the study is "an excellent example of how the NCDR Registry can be used to generate meaningful tools for prediction of complications that are set up for external validation from populations outside of the United States." He adds that because there are increasing numbers of patients with advanced kidney disease undergoing angioplasty, "there is an urgent need for safer approaches for these high-risk patients."
-end-
The American College of Cardiology is a 52,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.

The Journal of the American College of Cardiology, which publishes peer-reviewed research on all aspects of cardiovascular disease, is the most widely read cardiovascular journal worldwide. JACC is ranked No. 1 among cardiovascular journals worldwide for its scientific impact.

American College of Cardiology

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.